CME
CME Group Inc.
CME's fundamentals are mixed: revenue grew 9%, while its operating margin held steady at 66%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CME Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| N/A | |
| N/A |
CME's profitability is currently strong, and its revenue is stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like CME.
CME PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 24x | $289 | -8.3% |
| Forward | 24x | $316 | — |
| Fair | 26x | $314 | -0.4% |
| Current | 26x | $316 | — |
| Expensive | 33x | $405 | +28% |
Historical ranges are pointers, not guarantees.
CME's PE is 26x, but its earnings don't support one, so it isn't a reliable read right now.
CME Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for CME, with profitability improving.
CME Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $12.95 | +6.2% |
| Q3 2026 | $12.19 | +18% |
| Q2 2026 | $11.79 | +14% |
| Q1 2026 | $11.72 | +18% |
| Q4 2025 | $11.16 | +15% |
| Q3 2025 | $10.32 | +8.6% |
| Q2 2025 | $10.33 | +14% |
| Q1 2025 | $9.94 | +13% |
| Q4 2024 | $9.67 | +9.1% |
CME's earnings per share have climbed steadily: $12.19 over the past year, up 18% from the year before, and higher year over year for 21 quarters in a row. Its recent earnings include one-off gains.
CME Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.7B | +13% |
| Q2 2026 | $1.7B | +0.8% |
| Q1 2026 | $1.9B | +14% |
| Q4 2025 | $1.6B | +8.1% |
| Q3 2025 | $1.5B | -3% |
| Q2 2025 | $1.7B | +10% |
| Q1 2025 | $1.6B | +10% |
| Q4 2024 | $1.5B | +6% |
CME's revenue has grown year over year for four quarters in a row: $1.7B last quarter, up 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 66% | +2.5 points |
| Q2 2026 | 65% | -1.8 points |
| Q1 2026 | 70% | +2.2 points |
| Q4 2025 | 62% | -0.3 points |
| Q3 2025 | 63% | -1.4 points |
| Q2 2025 | 67% | +1.4 points |
| Q1 2025 | 67% | +3 points |
| Q4 2024 | 62% | +2.1 points |
CME's operating margin was 66% last quarter, up 2.5 points from the same quarter a year ago.
CME Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +13% |
| Q2 2026 | $923.5M | -11% |
| Q1 2026 | $1.2B | +12% |
| Q4 2025 | $1.1B | +11% |
| Q3 2025 | $949.7M | -2.4% |
| Q2 2025 | $1B | +37% |
| Q1 2025 | $1.1B | +26% |
| Q4 2024 | $991.7M | -3.1% |
CME's free cash flow was $4.3B over the past year, up 6.1% from the year before. Free cash flow isn't a meaningful measure for financial services companies like CME.
CME Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -2.6M shares |
| 1 year | -0.5% | -1.8M shares |
| 3 years | -0.3% | -978K shares |
| 5 years | -0.1% | -347K shares |
| Available history | +0.1% | +402K shares |
CME has 359M diluted shares, about the same as a year ago.
CME Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2020 | -0.4x | Net Cash |
| Q2 2020 | -0.4x | Net Cash |
| Q1 2020 | -0.3x | Net Cash |
| Q4 2019 | -0.6x | Net Cash |
CME has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like CME.
CME Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 65.2 | Neutral |
| Stochastic | 89.3 | Overbought |
CME's weekly RSI is 65 (neutral) and its Stochastic is 89 (overbought).
CME PE vs Financial Services Sector
| Metric | CME | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 13x | 99% above |
| PE % | 51 | 63 | 12 pts below |
CME is trading at 26x earnings, a 99% premium to the Financial Services sector's median of 13x, though its earnings don't support one.
CME Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $291.5 | 8.2% above |
| 20 week MA | $275.2 | 15% above |
| 50 week MA | $280.9 | 12% above |
| 100 week MA | $272.5 | 16% above |
| 200 week MA | $238.3 | 32% above |
CME is in an uptrend: it's above all five of its weekly moving averages, and 32% above its 200-week average.
CME Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $202.8 | $178.5 | -12% |
| 2021 | $178.5 | $229.0 | +28% |
| 2022 | $229.0 | $173.3 | -24% |
| 2023 | $173.3 | $210.6 | +22% |
| 2024 | $210.6 | $233.5 | +11% |
| 2025 | $233.5 | $276.7 | +19% |
| 2026 YTD | $276.7 | $315.5 | +14% |
CME has finished higher in four of the last six years. It's up 14% so far in 2026.